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tion with treatment in chronic health conditions. However, responsiveness (sensi-
tivity to change) still remained unknown. Thus, the goal of this study in a
prospective cohort of subjects with refractory Neuropathic pain (NeP) was to ex-
plore the ability of SATMED-Q to detect changes in patient=s satisfaction with
therapy. METHODS: We used data from a 6-month cohort prospective study car-
ried-out in pain clinics, which included patients with NeP referred to pain clinics to
change their pain therapy because of its resistance to previous treatments (pain
score in a 0-100 mm VAS above 40 mm after, at least, one course of an analgesic at
standard doses. Sensitivity to change of the SATMED-Q was assessed by mean of
comparing changes in the overall and sub-domains satisfaction scores between
baseline and end-of-trial visits according with patients response criterion; end-of-
trial pain reduction 50% (responder). Also, correlations between baseline to end-
of-trial change in pain intensity and satisfaction scores were computed. RESULTS:
The sample was formed with 755 subjects with refractory NeP; mean age: 57.8
years, 60.6% women, mean pain score of 74.2 (15.1) mm. After changing their ther-
apy, 47% of patients were considered responders, and pain intensity was reduced
by an average 42.9% (32.4), p0.001, which was significantly correlated (r-0.524,
p0.001) with overall treatment satisfaction improvement in SATMED-Q which
varied from 50.3 (17.3) to 74.2 (14.4) pts, p0.001. Pearson r-coefficients between
pain variation and SATMED-Q subdomains changes were significant and ranged
between -0.189 and -0.465 (p0.01 in all cases). Overall sore in SATMED-Q was
significantly higher in responders than in non-responders; 80.9 (79.6-82.3) versus
66.5 (65.0-98.0), respectively, p0.001. CONCLUSIONS: The SATMED-Q demon-
strated to be sensitivity to patient=s satisfaction with treatment change in resistant
NeP patients.
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ATTACHING VALUE TO NON-EFFICACY METRICS: A PRICING STUDY
Forster L1, Kleinlankhorst E2, Sagar A2
1Double Helix Consulting, London, UK, 2Double Helix Consulting, London, Other -, UK
OBJECTIVES: With fewer products in the development pipeline new technologies
entering the market often rely on demonstrating alternative value offerings. Im-
provements in administration and patient convenience are often desired but our
aim is to discover whether this leads to a tangible pricing and reimbursement
opportunity. METHODS: In-depth analysis was conducted across an array of prod-
ucts in a variety of disease areas where improvements in administration were the
only main differentiating factor. A variety of national and regional payers were
interviewed across European markets to gain an understanding of the value attrib-
uted to these factors. Payer advising key opinion leaders, influential in aiding de-
cision making, were also key to the research as they gave a more clinical perspec-
tive. In addition to value seen through administration, other endpoints such as
quality of life were assessed in terms of offering a potential price premium. Qual-
itative analysis of these findings permitted us to place markets in the framework
and extrapolate key findings to other key markets. RESULTS: With increased scru-
tiny of new medicinal products entering European markets since the economic
uncertainty of the past 2 years, administration advantages only pertain to a mar-
ginal price premium opportunity. Priority, in terms of pricing potential, is predom-
inantly derived from value attributed to a product’s efficacy. CONCLUSIONS:
Stakeholders, while enthusiastic about products offering patient advantages, had a
low willingness to pay for administration improvements. Physicians however were
more positive towards the value they placed on patient convenience and would be
willing to pay for administration and quality of life advances.
PRM2
THE REPORTING OF OBSERVATIONAL STUDIES IN SPAIN: ANALYSIS USING THE
STROBE STATEMENT
Galera J, Lahoz R, Roig F
Novartis Farmacéutica, S.A., Barcelona, Spain
OBJECTIVES: To assess the communication of observational studies of Cardiovas-
cular and Metabolism therapeutic area (CVM) published in 6 Spanish journals in
2009 using the STROBE statement (Strengthening the Reporting of Observational
Studies in Epidemiology). METHODS: It were identified all published observational
studies in Atención Primaria, Gaceta Sanitaria, Hipertensión, Medicina Clínica, Re-
vista Clínica Española y Revista Española de Cardiología related to CVM therapeutic
area. For each paper, three independent reviewers applied the 34 items of the
STROBE statement. RESULTS: Throughout 2009, 74 CVM observational studies
were published in the evaluated journals. The most frequent design was prospec-
tive (43.15%) and cross-sectional (37.5%), and the least retrospective (19.4%). The
study main objective was on pathology (74.3%), followed by drug and non-pharma-
cological interventions (20.3%) and diagnosis (5.4%). The mean of complied items
was 20 on 34 (SD  3.7), with a maximum of 24 (SD  2) in Gaceta Sanitaria and a
minimum of 19 (SD  2.8) in Hipertensión. The Methods and Results sections
showed more deficiencies. CONCLUSIONS: Evaluated papers comply with slightly
more than a half items (58%) of the STROBE recommendations. Increasing STROBE
use could improve the quality of the communication of these studies results, pro-
viding greater transparency for analysis and increasing its usefulness in clinical
practice.
PRM3
CHALLENGES TO OBTAIN REAL-LIFE DATA IN OBSERVATIONAL STUDIES:
WHAT ARE THE SOLUTIONS WHEN THE PATIENT IS THE MAIN DATA
PROVIDER?
El kebir S1, Bourhis Y2, Fournie X3
1Regsitrat Mapi, Lexington, KY, USA, 2Regsitrat Mapi, Lyon, France, 3Registrat Mapi, Lyon,
France
BACKGROUND: Collecting patients’ data in observational longitudinal studies is
often a concern in terms of data accuracy and patient follow up. Depending of the
study design, the physicians’ assessment might be not sufficient and/or non-fea-
sible. Direct to patient contact (DtPC) process is commonly used to maximize the
long-term follow up and ensure continuity and quality in data collection.
OBJECTIVES: To demonstrate the benefit of DtPC, through example of multina-
tional study. Challenges were to implement feasible and robust methods to collect
and confirm Events of Interest for the study (EoI) in ‘real-life’ settings, fitting health
care standards, regulatory and cultural requirements of countries involved.
METHODS: Longitudinal, international, observational study. Enrolling physicians
were not primary patient’s Health Care Providers; consequently, patients had to be
the main contact to capture the EoI. Patients had to complete and sign a Contact
Order Form that allowed trained interviewers performing follow-up calls at regular
time points during the follow up period. Baseline clinical and demographic data
were collected by enrolling physicians. Then, the medical confirmation of EoI de-
tected through telephone interviews was ensured by the involvement of the con-
cerned EoI’s treating physician. RESULTS: On average 85% successful interviews
were performed, 2% patients withdrawn their consent, 3% patients were lost to
follow up. On average, 80% of the EoI’s treating physicians accepted the process for
medical confirmation and data collection of the EoI, despite strong variations de-
pending on the country.CONCLUSIONS:The results of this study are in accordance
with our previous experiences and confirms the benefits of using DtPC in interna-
tional observational and longitudinal studies. This process enabled a harmonised
and centralised method to obtain real life data overview for all patients included,
whatever their country, a high level of patient adherence and a low rate of patient
withdrawal, despite the large number of countries involved.
PRM4
MEASURING COMORBIDITY IN ADMINISTRATIVE DATA
Hermansson J1, Carlqvist P2, Kennedy K3, Pietri G3
1Heron AB, Stockholm, Sweden, 2Heron AB, Stockholm, Stockholm, Sweden, 3HERON Evidence
Development Ltd, Luton, UK
OBJECTIVES: Comorbidities, conditions or diseases besides the one of primary
interest is often measured using a comorbidity index condenses all the coexistent
conditions to a single score. As the use of administrative data is gaining more and
more attention within health economics there is a need for summarising the in-
dexes validity such use. The objective of this study was to review published meth-
ods to measure comorbidity in administrative data. METHODS: A structured
search, using as primary search terms comorbidity, multimorbidity, and coexisting
disease, to find comorbidity indexes validated for use in administrative data anal-
ysis was undertaken in Embase.com to identify studies published since 2000 in
which an index to measure comorbidity was described. For purposes of validation,
correlation coefficients, ratios, explained variance, and the area under the receiver
operating characteristic curve were used. Regression models predicting future
events that were significant or significantly improved after adding comorbidity as
a covariate was considered to support validity. Parameters used to assess reliability
were among others correlation coefficients. RESULTS: Sixtyfour publications were
studied resulting in two different indexes, to measure comorbidity in administra-
tive data were identified. The Charlson Comorbidity Index (CCI) generated the
greatest number of studies on comorbidity assessment in administrative data and
it had the most consistent results regarding validity and reliability. CCI compiles
the weighted mortality association of nineteen different diseases with a number of
adaptations for specific circumstances. CONCLUSIONS: The main finding is that
the CCI remains the most used and validated index for assessment of comorbidity
in administrative data. Assessment of comorbidity is an area of interest for both
health economists and epidemiologists and it seems to be receiving increased
attention.
PRM5
NOVEL PATIENT REPORTED OUTCOMES AND DATA TOOL FOR CHRONIC
DISEASE MANAGEMENT (PROCDIM): CASE IN POINT PROSTATE CANCER
Aggarwal S
Novel Health Strategies, Bethesda, MD, USA
OBJECTIVES: Patient Reported Outcomes (PROs) play an important role in evaluat-
ing patient quality of life and comparative efficacy of various treatments. Another
potential use of PROs is for chronic disease management, which can provide useful
data to physicians and patients. We developed a novel web and phone based PROs
tool for management of prostate cancer disease.METHODS: PRO methods for pros-
tate cancer were reviewed by analyzing published clinical studies. KOLs and pa-
tient advocacy groups were interviewed to obtain their input for design of PRO
disease management tool. Recent technologies for developing such tools were re-
viewed by analyzing available electronic PRO tools. PROCDIM design was devel-
oped based on secondary research and primary interviews. RESULTS: PROCDIM
was designed to capture patient reported outcomes data such as Quality of Life
(using five attributes), adverse events (six commonly reported AEs), medications
and OTC drugs history, PSA antigen score, past surgery and radiation therapy and
record of physician appointments. Patients could enter data into PROCDIM using
web or phone (iphone or andriod) based systems. Data from PROCDIM could be
emailed by patient to provider or could be downloaded by tethering phone to
computer. Pilot data was captured by testing PROCDIM with physicians and patient
advocacy groups. Based on interviews, PROCDIM was rated superior and highly
user friendly compared to current chronic disease management tools. Patient out-
comes data would be collected from a planned IRB approved study.CONCLUSIONS:
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PROCDIM is a valuable tool to capture several patients reported outcomes and data
for chronic disease management. Such tools could be used for collecting data for
disease management, clinical trial and for observational studies for various
chronic diseases.
PRM6
VALIDATING AN ALTERNATIVE WEIGHTING ALGORITHM OF THE CHARLSON
COMORBIDITY INDEX (CCI) FOR RISK ADJUSTMENT IN PREVIOUSLY
HOSPITALIZED PATIENTS
Cheng LI, Rascati KL
University of Texas at Austin, Austin, TX, USA
OBJECTIVES: To validate an alternative weighting algorithm of the Charlson Co-
morbidity Index (CCI) for the prediction of health care expenditures and utilization
in previously hospitalized patients.METHODS:Data from the Medical Expenditure
Panel Survey (MEPS) Panel 12 (2007-2008) were retrieved for this retrospective co-
hort study. Two CCI scores were calculated for patients who were hospitalized in
2007: one based on the original weights (Charlson-CCI) and the other based on the
weights updated by Quan et al. (Quan-CCI) [both were developed to predict mor-
tality]. Adjusted R2 from linear regression models were used to estimate log-trans-
formed healthcare expenditures (COST) in 2008. Odds ratios and c statistics from
logistic regression models were used to compare the predictive power of the risk of
hospitalizations ( 1 admission), risk of emergency department visits ( 1 visit),
and high expenditures ( 90th percentile of COST) in 2008. RESULTS: Seven hun-
dred patients who had been previously hospitalized were included in the study.
The mean (SD) age was 52.5 (15.3) years, and 65% were female. In the linear regres-
sions, the Charlson-CCI explained more variance in COST than the Quan-CCI (ad-
justed R2  20.7% vs. 19.9%), adjusting for age and sex. The Charlson-CCI was a
better predictor of the risk of emergency department visits (c0.600) than the
Quan-CCI (c0.571). Compared with the Quan-CCI, the Charlson-CCI showed bet-
ter discriminatory power for the prediction of high-expenditure individuals
(c0.770 vs. 0.743) and the risk of hospitalizations (c0.589 vs. 0.581). The Quan-CCI
did not significantly predict high-expenditure individuals (OR1.15; 95% CI0.99-
1.33) or the risk of hospitalizations (OR1.14; 95% CI0.99-1.30). CONCLUSIONS: In
a group of previously hospitalized patients, the original CCI exhibited better dis-
crimination for the prediction of healthcare expenditures, hospitalizations, and
emergency department visits. The weights updated by Quan et al. were developed
to predict mortality and may have limited utility in predicting health care utiliza-
tion.
Research On Methods – Cost Methods
PRM7
USING PROBABALISTIC SENSITIVITY ANALYSIS IN BUDGET IMPACT MODELS
TO REDUCE UNCERTAINTY AND IMPROVE DECISION-MAKING
Latif F, Roberts G
Double Helix Consulting, London, UK
OBJECTIVES: Budget impact analysis (BIA) is formally required by many national
HTA regulatory agencies including NICE and the PBAC, in the UK and Australia,
respectively. Current practice only involves the use of point estimates to serve as
“best guess” for decision-makers. However, using probabilistic sensitivity analysis
(PSA) can serve to reduce parameter uncertainty in order to generate discussion
and ultimately improve decision-making. METHODS: Using the same techniques
applied to cost-effectiveness analysis, a PSA was incorporated into a budget impact
model used for a client’s medical device. This involved creating and running a
Monte-Carlo simulation (MCS) over 10,000 iterations to generate a 95% confidence
interval (CI) around the overall budget impact in addition to a probability curve.
RESULTS: Point-estimate budget impact was found to be a saving of £4,736,893
based on a number of pre-defined input parameters in the model. Running a MCS
generated a 95% CI: a saving of £10,367,403 and an incremental cost of £861,166
either side of the point-estimate. In addition, a probability curve was generated
with overall budget impact on the x-axis and probability on the y-axis. 25 data
points were generated running from a maximum potential saving of approxi-
mately £12m (1% probability) to an incremental cost of approximately £3m (100%
probability). CONCLUSIONS: Using PSA in this budget impact model demonstrates
that there is a significant likelihood this medical device could actually generate an
incremental cost rather than saving (which the point-estimate shows). This serves
as an example of how using this technique could serve to generate discussion
among decision-makers in order to make more informed and improved budget
impact decisions in the future.
PRM8
COULD CORPORATE SOCIAL RESPONSIBILITY PREDICT PHARMACEUTICAL
CORPORATE FINANCIAL PERFORMANCE?
Auamnoy T, Areepium N
Chulalongkorn University, Bangkok, Thailand
OBJECTIVES: 1) To quantify CSR concept by developing a pharmaceutical compa-
nies namely Auamnoy’s visual analogue scales—a 24 measurement indicators in 6
dimensions to make a composite variate; 2) To perform a retrospective research to
explore relationship between CSR activities and corporate financial performance
(CFP); and 3) To discover prediction model to predict pharmaceutical CFP by CSR.
METHODS: Challenging literature reviews were executed on and on to find the
valid and reliable scales to measure CSR. Twelve appropriate CFP indicators were
discussed and then selected to evaluate 43 pharmaceutical companies perfor-
mance. The  value was set at 0.05, one side using SPSS version 17.0 to calculate all
statistical analysis. RESULTS: The six dimensions Auamnoy’s scales were Drug
development, Patients, Environment and safety, Social issues, Philanthropy and
Business ethics and – yielded acceptable Cronbach’s alpha 0.7415, 0.7154, 0.7151,
0.7426, 0.7217 and 0.7466 respectively. Pearson’s product moment correlation con-
firmed that CSR showed a significant positive correlated with (ROI, Sales, EPS, DPS,
BV, %Sales Growth, %ROA and %ROI) (r0.832, 0.489, 0.789, 0.631, 0.351,
0.298,0.455,0.336, p0.000, 0.000, 0.000, 0.000, 0.011, 0.030, 0.001, 0.008 respec-
tively). Finally, Regression analysis estimated significant seven models of pharma-
ceutical CFP–ROI, Sales, EPS, DPS, BV, %ROA and %ROI by CSR. CONCLUSIONS: The
answer was yes, pharmaceutical CSR could predict CFP. The more the pharmaceu-
tical companies invested in CSR. the more CFP they obtained.
PRM9
WHAT GUIDANCE IS AVAILABLE FOR BUDGET IMPACT ANALYSIS?
Kusel J1, Costello S2
1Costello Medical Consulting Ltd, Cambridge, UK, 2Costello Medical Ltd, Cambridge, UK
OBJECTIVES: There is a wealth of literature and guidance available for cost-effec-
tiveness research, but the guidance available on budget impact analysis (BIA) is less
familiar to many investigators. In times of increased budget constraint, however,
the importance and popularity of BIA is growing. The objective of this review was to
assess whether guidance on BIA methodology is available and consistent.
METHODS: Online searches were performed to identify published guidelines or
recommendations on BIA from any country. The guidelines were then reviewed for
whether they gave advice on certain pre-determined methodological categories.
RESULTS: National guidelines have been produced in Canada, Ireland, Scotland
and Poland specifically on how BIA in each of these countries should be performed.
Other countries such as the UK, Italy and Hungary include recommendations on
BIA within guidelines on health care economic assessment, but their focus is
largely on cost-effectiveness analysis. The national guidelines were consistent in
whether they made recommendations on perspective and time horizon, but varied
in whether they gave advice on market share determination, sources of costs,
inclusion of treatment of adverse events and the presentation of resource use and
costs separately. The definition of the term ‘incremental BIA’ was also used incon-
sistently. An ISPOR Task Force has produced international guidance for budget
impact methodologies, which is designed to support national guidelines rather
than supersede them and also to improve consistency across BIAs developed for
different settings. CONCLUSIONS: Several national and international bodies have
developed guidelines or tools for developing and reporting budget impact models.
However, different specifications exist and not all methodological aspects are
made explicit in every case. Consensus guidelines such as those produced by the
ISPOR task force are required to shape future national BIA recommendations.
PRM10
TO GET THE RIGHT PRICE – A DECISION SUPPORT METHOD TO OPTIMIZE
MANAGERIAL DECISIONS ON PUBLIC FUNDING PRICE TO APPLY FOR
Wilk NM1, Kloc K2
1Arcana Institute, Krakow, Malopolskie, Poland, 2Arcana Institute, Krakow, malopolskie, Poland
OBJECTIVES: In challenging economic times public funding decision makers are
getting tougher, so the managers have to be smarter to choose the right price and
optimally justify it. The objective is to present our method which rationally sup-
ports managerial decisions on pricing in public funding. METHODS: The decision
support method consists of the following steps: 1) identify all arguments relevant
to different price levels – e.g. based on prices of similar drugs that were accepted by
public payer or related to prices of the drug in other countries; 2) calculate maxi-
mum price that may be justified with each piece of an argument; 3) sort arguments
in price ascending order; 4) rank arguments in a pairwise manner against their
impact on probability of public funding acceptance using 5-point Likert scale; 5)
plot all arguments on a graph with price level on X axis and cumulative impact on
probability of acceptance on Y axis; and 6) calculate first derivative to identify local
maxima. The seventh step is the manager’s decision on choosing the right price
from the subset of local maxima. Local maxima represent the price levels for which
a relatively large increase in price associates with a relatively small decrease in
acceptance for public funding. RESULTS: The decision support analysis results in a
subset of price levels that the manager is recommended to choose the right price
from. The final choice may depend on acceptance/avoidance of risk or necessity to
achieve a specific turnover. All arguments that justify the chosen and higher prices
may be used to justify this price to public funding decision makers.CONCLUSIONS:
To ensure a pricing success to their companies and their own career development
Market Access managers should use the presented decision support method to
make possibly best informed choices concerning official prices of their drugs.
PRM11
LEARNING EFFECT IN ECONOMIC EVALUATIONS OF HEALTH CARE
INTERVENTIONS
Chang S, Sungher D, Diamantopoulos A
Symmetron Limited, Elstree, Herts, UK
OBJECTIVES:The presence of the learning effect has an impact on the effectiveness
of health technologies and so, it is relevant to capture this in an economic analysis.
The aim of this study is to explore the bibliography of learning curves in health care
economic evaluations. METHODS: In order to understand the bibliography of
learning curves in economic evaluations, a systematic review was conducted to
identify economic analyses that include a formal description of a learning effect.
The following databases were searched: Medline, Medline (R), Embase, EconLIT,
HEED and NHS EED. For a study to be included in the review, it had to be an
economic evaluation defined as a cost, utility or cost-effectiveness study. In addi-
tion, the study also had to formally analyse the learning effect by using statistical
analysis, graphs or tables. All non-human and non-English studies were also ex-
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